Module

Advances in the Frontline Treatment of Multiple Myeloma

Source: Novel Approaches in Frontline Multiple Myeloma Therapy: Understanding the Options and Implications for Transplantation

Advances in the Frontline Treatment of Multiple Myeloma


Faculty:

Amitabha Mazumder, MD
  • Amitabha Mazumder, MD

CME CREDIT INFORMATION

Release Date: 06/12/08

Expiration Date: 06/11/09


Physicians: maximum of 1.0 AMA PRA Category 1 Credit

Status: Please log in to view status


Begin the Module

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain disease staging in the clinical management of patients with multiple myeloma
  • Discuss the use of bortezomib, both as monotherapy and in combination regimens, in the treatment of multiple myeloma
  • Describe the role of stem cell transplantation in the clinical management of patients with multiple myeloma
  • Articulate differences in treatment options and approaches for elderly vs younger patients with multiple myeloma

Topics covered include:

  • Multiple Myeloma: Introduction and Background
  • New Concepts in Criteria for Diagnosis, Prognosis, and Response
  • Bortezomib in First-Line Therapy for ASCT-Eligible Patients
  • Lenalidomide in First-Line Treatment for ASCT-Eligible Patients
  • Stem Cell Transplantation in the Modern Era
  • Expanding First-Line Treatment Options for Multiple Myeloma Patients Not Eligible for ASCT
  • Steroid-Free Therapies
  • Pegylated Liposomal Doxorubicin Combination Regimens
  • Conclusions


Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

This educational program has been supported by

Educational grants support only the CME-certified components of this program.